Epilepsy is a clinical multiaxial diagnosis.
Epileptic seizure is a transient occurrence of signs/symptoms brought about by abnormal excessive or synchronous neuronal activity in the brain.
It is recommended that all patients having a first seizure be referred as soon as possible to a specialist to ensure accurate and early diagnosis and initiation of treatment appropriate to the needs of the patients.
Midazolam nasal spraydelivers prompt and prolonged seizure control with a favourable safety profile in the outpatient treatment of patients experiencing a seizure cluster, according to the results of the phase III ARTEMIS-1* trial.
New drug applications approved by US FDA as of 16 - 31 May 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A low sodium concentration in the blood is commonly observed in patients with epilepsy, with moderate and severe hyponatraemia associated with reduced bone mineral density in the lumbar spine, a study has found.
A broad range of peripheral infections, including those of the central nervous system, appears to be associated with a heightened risk of developing epilepsy, potentially due to inflammatory processes affecting the brain, according to a study.
Combination therapy increases the chance of achieving seizure freedom in patients who have failed their first antiepileptic drug due to lack of efficacy as compared with alternative therapy or dose escalation, a study has shown.
Inpatients with refractory epilepsy often have probable obstructive sleep apnoea (pOSA), and those with pOSA are older, heavier and more likely to have focal seizures and longer disease duration, a study reports.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.